Eyevensys

Eyevensys is using its EyeCET gene therapy electroporation technology, which enables the sustained intraocular production of a range of therapeutic proteins, to develop a pipeline of products that overcome the limitations of existing invasive treatments and address unfulfilled therapeutic needs.


Headquarters
Eyevensys SAS,
Tour Montparnasse,
33 Avenue du Maine,
75015 Paris,
France

Phone / Contact

T: +33 1 84 79 10 60
Top